Velsera's Innovation in Real-World Data for Pharma Success
Revolutionizing Data Access for Drug Development
In a world where data is increasingly vital in healthcare, Velsera stands out by redefining how pharma and biotech enterprises access real-world, longitudinal clinicogenomic data. The company's Global Data Network (GDN) is presenting innovative solutions that bridge the gap between data silos and actionable insights.
Transformative Global Data Network Approach
Velsera's GDN encompasses over 175 million patient records obtained from more than 50 global data providers. This extensive reach is crucial as it connects various data sources such as electronic medical records (EMR), genomics, proteomics, transcriptomics, pathology, and radiology. With this unified network, Velsera is facilitating a shift in drug discovery timelines, allowing access to critical data in a matter of weeks rather than years.
Addressing Industry Challenges
In an industry where traditional data acquisition can extend into long, frustrating years, the necessity for a more efficient method can't be overstated. Jamie Littlejohns, Chief Executive Officer at Velsera, highlighted the staggering statistic that 97% of healthcare data remains untapped, a situation that demands immediate action. With the GDN, pharmaceutical and biotech firms can derive actionable insights from vast datasets, ensuring both compliance and data security.
A Federated Model for Enhanced Security
Unlike centralized systems that often grapple with security vulnerabilities, Velsera's federated approach allows secure access to sensitive data while maintaining the autonomy of source institutions. This innovative model preserves patient privacy and adheres to stringent regulations like GDPR and HIPAA. The GDN is positioned not only to provide a wealth of data but to do so responsibly.
Global Representation and Diverse Applications
The GDN’s data originates from numerous countries, with about 40% of the datasets sourced from outside the U.S. This ensures that the insights gleaned are globally relevant, particularly in key therapeutic areas such as oncology, immunology, neurology, and cardiometabolic diseases. With various high-impact use cases involving clinical and omics data, Velsera is addressing the pressing R&D needs in the pharmaceutical sector.
Accelerating Research and Development Initiatives
To streamline R&D processes, Velsera has developed a well-structured system. Their talented team of data scientists collaborates closely with clients, ensuring that data is not only sourced but also properly harmonized for effective usage. Remarkably, 80% of data requests are fulfilled in weeks, empowering biopharma partners with timely insights essential for decision-making.
Flexible Engagement Models for Diverse Needs
Understanding that different organizations may have varying needs, Velsera offers flexible engagement models. From extended collaborations to short-term access, this flexibility allows teams across the pharmaceutical landscape to pilot high-value initiatives with swiftness and precision. The goal is clear: not just to deliver data but to create a comprehensive infrastructure for action.
About Velsera
Velsera is dedicated to becoming a leading platform in discovery, evidence generation, and clinical application of precision medicine. By empowering experts in clinical diagnostics and life sciences, Velsera aims to refine the decision-making process for delivering optimal therapies to patients. Established in 2023 through a strategic merger, the company continues to expand its reach and impact in the U.S., Europe, and Asia.
Media Contact
Brian Lassiter
Senior Manager, Growth Marketing
Velsera
(857) 357-3060 | ext 3060
Frequently Asked Questions
What is the Global Data Network (GDN) by Velsera?
The GDN is a federated data ecosystem that connects various data sources, enabling efficient access to clinicogenomic data for drug development.
How does Velsera ensure data security?
Velsera utilizes a federated approach to keep sensitive data under the control of its source institutions while allowing secure access.
What is the impact of Velsera’s network on drug discovery timelines?
The GDN significantly reduces the time needed to transition from data requests to actionable insights, optimizing the drug discovery process.
What areas are covered by Velsera’s GDN data?
The GDN offers global relevance across various therapeutic areas including oncology, immunology, neurology, and cardiometabolic diseases.
What engagement models does Velsera offer?
Velsera provides flexible engagement options, ranging from multi-year partnerships to short-term data access, accommodating diverse organizational needs.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.